132 related articles for article (PubMed ID: 12243953)
1. Interferon as adjuvant treatment for melanoma.
Wheatley K; Ives N; Hancock B; Gore M
Lancet; 2002 Sep; 360(9336):878. PubMed ID: 12243953
[No Abstract] [Full Text] [Related]
2. Malignant melanoma: non-metastatic.
Crosby D; Crosby T; Mason M
Clin Evid; 2002 Jun; (7):1519-29. PubMed ID: 12230768
[No Abstract] [Full Text] [Related]
3. Adjuvant interferon: extended follow-up times needed?
Thoren FB; Strannegård Ö
Lancet Oncol; 2011 May; 12(5):419. PubMed ID: 21536217
[No Abstract] [Full Text] [Related]
4. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
Agarwala SS; Gray RJ; Wong MK
J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
[No Abstract] [Full Text] [Related]
5. Management of cutaneous melanoma.
Tsao H; Atkins MB; Sober AJ
N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
[No Abstract] [Full Text] [Related]
6. Adjuvant interferon-alpha improves skin cancer survival.
Kerr C
Lancet Oncol; 2002 May; 3(5):262. PubMed ID: 12067791
[No Abstract] [Full Text] [Related]
7. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta E
Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
[No Abstract] [Full Text] [Related]
8. The role of adjuvant interferon in high risk melanoma patients.
Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
[No Abstract] [Full Text] [Related]
9. High-dose adjuvant interferon therapy for melanoma.
Licata AG
Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
[TBL] [Abstract][Full Text] [Related]
10. Node positive melanoma--a positive note?
Kelly J; Kerin MJ
Surgeon; 2012 Apr; 10(2):63-4. PubMed ID: 22385525
[No Abstract] [Full Text] [Related]
11. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
Lens M
Dermatol Ther; 2006; 19(1):9-18. PubMed ID: 16405565
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant interferon therapy for melanoma.
Hancock B; Wheatley K; Ives N; Gore M
J Clin Oncol; 2005 Apr; 23(10):2431; author reply 2431-2. PubMed ID: 15800339
[No Abstract] [Full Text] [Related]
13. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
[No Abstract] [Full Text] [Related]
14. Update on the role of adjuvant interferon for high risk melanoma.
Agarwala SS; Kirkwood JM
Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
Kirkwood JM; Resnick GD; Cole BF
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
[TBL] [Abstract][Full Text] [Related]
16. Choices in adjuvant therapy of melanoma.
Lawson DH
Cancer Control; 2005 Oct; 12(4):236-41. PubMed ID: 16258495
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon for melanoma.
Wheatley K; Ives N
Ann Oncol; 2002 Aug; 13(8):1319-20; author reply 1320. PubMed ID: 12181258
[No Abstract] [Full Text] [Related]
18. Adjuvant interferon alfa-2b for high-risk melanoma.
Retsas S
J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
[No Abstract] [Full Text] [Related]
19. Adjuvant interferon in the treatment of melanoma.
Kirkwood JM
Br J Cancer; 2000 May; 82(10):1755-6. PubMed ID: 10817514
[No Abstract] [Full Text] [Related]
20. [After removal of a malignant melanoma. Enhancing the immune system!].
MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
[No Abstract] [Full Text] [Related]
[Next] [New Search]